Recent Quotes (30 days)

You have no recent quotes
chg | %

Nuvo Research Inc  

(Public, TSE:NRI)   Watch this stock  
Find more results for NRI
-0.20 (-2.63%)
Nov 26 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 7.38 - 7.60
52 week 1.66 - 8.33
Open 7.60
Vol / Avg. 37,582.00/85,822.00
Mkt cap 76.99M
P/E 1.83
Div/yield     -
EPS 4.05
Shares 10.40M
Beta 0.28
Inst. own     -
Nov 10, 2014
Q3 2014 Nuvo Research Inc Earnings Release
Sep 9, 2014
Nuvo Research Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 1653.92% -56.37%
Operating margin 1615.45% -56.67%
EBITD margin - -11.76%
Return on average assets 435.80% -41.42%
Return on average equity 565.29% -61.65%
Employees 79 -
CDP Score - -


Unit 10, 7560 Airport Road
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)

Website links


Nuvo Research Inc. is a specialty pharmaceutical company. The Company is engaged in building a portfolio of products for the treatment of pain through internal research and development (R&D), in-licensing and acquisition. The Company�s product portfolio includes Pliaglis and Synera. Through its subsidiary Nuvo Research AG, the Company is also developing the compound WF10, for the treatment of immune related diseases. The Company�s Pain Group located in West Chester, Pennsylvania is focused on the development and commercialization of topically delivered pain products, including Pennsaid.

Officers and directors

Daniel H. Chicoine Chairman of the Board, Co-Chief Executive Officer
John C. London President, Co-Chief Executive Officer, Director
Stephen L. Lemieux Chief Financial Officer, Vice President
Henrich R. K. Guntermann M.D. President of Europe and Immunology Group, Director
Bradley S. Galer M.D. President of Pain Group
Age: 52
Katina Loucaides Vice President, General Counsel, Secretary
David A. Copeland Lead Independent Director
Anthony E. Dobranowski Independent Director
Jacques Messier Independent Director
Theodore H. Stanley M.D. Independent Director
Age: 73